 Dear Reader, On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." The man who defended the US dollar for 60 years just told you it's done. Ray Dalio agrees. 
Source: International Business Times
The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." $38.4 trillion in debt. Adding a trillion every 60 days. A billion every 8 hours. The math doesn't work anymore. If the dollar falls, most people will get hurt badly. But there's a specific asset class and investment system that actually thrives when the dollar collapses. It's called the ABN System. It adapts the principles of Blackrock's investing strategy so everyday investors can apply it to protect themselves. Over 4,500 members have already implemented this system. If you have $50k+ exposed to the dollar right now (including your 401(k), stocks, real estate, savings), you need to pay attention. Watch how to protect yourself from what Dalio and Buffett see coming (free training) -> To your freedom,
Tan Gera, CFA©
Decentralized Masters P.S. JPMorgan warned we're at 120% debt-to-GDP. Greece collapsed at 130%. Watch the presentation now.
Exclusive Content
2 Biotech Stocks Shaping Up for Major BreakoutsReported by Ryan Hasson. Article Posted: 8/22/2026. 
Key Points
- Moderna's mRNA cancer vaccine, developed with Merck, succeeded in a late-stage melanoma trial, sending shares up 177% and boosting the broader biotech sector.
- Eli Lilly, the world's largest pharmaceutical company, is nearing a 52-week high driven by its GLP-1 franchise and new oral-drug pipeline catalyst.
- Natera has surged over 40% year to date on accelerating revenue growth and analyst support, though its rich valuation reflects a momentum-driven growth profile.
- Special Report: ALERT: Drop these 5 stocks before the market opens tomorrow!
The biotech sector just received the kind of catalyst that can define a cycle. On Wednesday, Moderna (NASDAQ: MRNA) stunned the market when its personalized mRNA cancer vaccine, developed with Merck (NYSE: MRK), became the first such therapy to succeed in a late-stage trial, reducing the risk of melanoma recurrence. The stock closed up an astonishing 177%, and the implications extend far beyond a single company. The results represent a landmark validation of the broader mRNA platform and a potential turning point for cancer treatment itself.
The news landed as the sector was already surging. The iShares Biotechnology ETF (NASDAQ: IBB) is up about 25% year to date, with much of that growth coming in the last 30 days. During that period, the ETF hit a fresh 52-week high, demonstrating the kind of strength that tends to draw new money off the sidelines. With Moderna's breakthrough adding fuel to that momentum, biotech's leadership may strengthen further. Two biotech names that have quietly built powerful uptrends throughout this run and now look poised to break out are Eli Lilly (NYSE: LLY) and Natera (NASDAQ: NTRA). Eli Lilly: The Pharma Giant Still Dominating Its MarketEli Lilly is the world's largest pharmaceutical company by market capitalization, a $1.2 trillion healthcare titan anchored by its blockbuster GLP-1 franchise. Even at that scale, the stock continues to climb, rising more than 15% year to date and jumping about 4% on Wednesday alone to close just below its 52-week high.
The freshest catalyst is Lilly's push into oral GLP-1 medications, a next-generation format that could significantly expand the weight-loss and diabetes markets beyond today's injectables and open the door to hundreds of millions of new patients.
That opportunity builds on an already dominant foundation, as Lilly's existing treatments continue to outpace rival Novo Nordisk (NYSE: NVO) in sales growth. A company this size rarely has both entrenched market leadership and a genuine new growth avenue, but Lilly has both. On the analyst front, Lilly carries a Moderate Buy consensus across 30 analysts, while its news sentiment score ranks among the strongest in large-cap healthcare. The stock hit a new 52-week high on Wednesday, breaking above a resistance level that had held for nearly three months. If the stock can hold above $1,250, a major prior resistance level, a breakout on a significantly higher time frame could be in the cards for this sector-leading giant. Natera: The Genetic Testing Leader Firing on All CylindersNatera offers a very different profile: It is a fast-growing diagnostics innovator specializing in cell-free DNA testing across reproductive health, oncology and organ transplantation. Its Signatera cancer-monitoring assay has become a standout product, and the company sits directly in the path of the precision-medicine wave sweeping through healthcare. Natera has soared more than 40% year to date, easily outpacing the sector benchmark. Since breaking out of its multimonth base in June, the stock has continued its powerful advance, driven by accelerating revenue growth. Annual sales now top $2.3 billion. The market is treating Natera as a genuine leader in its niche, and its status as a top-10 holding in the IBB underscores that standing. Analysts remain constructive, with a Moderate Buy consensus from 22 analysts. Just last week, Citi reiterated a Buy rating on the stock and raised its price target from $315 to $365. The one factor worth flagging is valuation. After such a run, Natera trades at a rich multiple of more than 20 times sales, making it a momentum-driven growth name rather than a value play. From a momentum perspective, the chart is also shaping up for another potential breakout. Following its recent earnings, the stock has spent several weeks consolidating near its 52-week highs and building a tight base. If NTRA pushes through its 52-week high, it could signal a breakout, with further upward momentum potentially following as the uptrend expands. 2 Leaders at a Pivotal MomentWhat makes these two names compelling right now is the timing. Both have already demonstrated strength through months of outperformance, and both enter this moment with sectorwide momentum at their backs following Moderna's historic breakthrough. Eli Lilly offers scale, dominance and a fresh oral-drug catalyst, while Natera brings explosive growth and leadership in precision diagnostics. With biotech breaking out as a group and these two stocks pressing against their highs, the setup is worth watching closely. As always, the charts will tell the final story, but the fundamental and sector backdrop could hardly be more supportive.
This content is for educational purposes only. The opinions expressed are from DM Intelligence LLC, doing business as Decentralized Masters, who are not licensed financial advisors or registered investment advisors. The reader acknowledges that DM Intelligence LLC is not responsible for any losses, direct or indirect, resulting from the use of this information, including errors, omissions, or inaccuracies. Results are not typical and will vary. Success with digital currencies requires time, effort, and involves substantial risk including total loss of investment. Past performance does not indicate future results. All investments are at your own risk. You may unsubscribe at any time.
. |
Tidak ada komentar:
Posting Komentar